Evidence map›Paper›PMID 32303954›Full record

ArticleEndocrine pathology2020

The Diagnostic Dilemma of GATA3 Immunohistochemistry in Pheochromocytoma and Paraganglioma.

Noriko Kimura, Kiyoto Shiga, Kenichi Kaneko, Chiho Sugisawa, Takayuki Katabami, Mitsuhide Naruse

Abstract read
PubMed Publisher
In one paragraph

Article in Endocrine pathology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.2field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Paraganglioma of the Head and Neck: A Review.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2023
    Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 6 institutions in 1 country.

Noriko KimuraDepartment of Diagnostic Pathology, National Hospital Organization Hakodate National Hospital, 18-16 Kawahara, Hakodate, Hokkaido, 041-8512, Japan. kimura.noriko.sf@mail.hosp.go.jp.ORCID https://orcid.org/0000-0001-8160-3687
Kiyoto ShigaDepartment of Head & Neck Surgery, Iwate Medical University Faculty of Graduate School of Medicine, Morioka, Iwate, Japan.
Kenichi KanekoDepartment of Otolaryngology-Head and Neck Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Chiho SugisawaDepartment of Diabetes, Metabolism, and Endocrinology, Showa University Fujigaoka Hospital, Yokohama, Kanagawa, Japan.
Takayuki KatabamiDepartment of Internal Medicine, Division of Metabolism and Endocrinology, St. Marianna University School of Medicine Yokohama City Seibu Hospital, Yokohama, Japan.
Mitsuhide NaruseDepartment of Endocrinology, Metabolism, and Hypertension, National Hospital Organization, Kyoto Medical Center, Kyoto, Japan.
Iwate Medical University · JPKyoto Medical Center · JPNagasaki University · JPNational Hospital Organization · JPShowa University Fujigaoka Hospital · JPSt. Marianna University School of Medicine · JP

Funding

Japan Agency for Medical Research and Development (AMED) JP19ek010935
6 · The paper itself

Abstract

Although GATA3 has been recognized as a useful marker for mammary and urothelial carcinomas, there is large variation in GATA3 expression detected in pheochromocytoma (PC) and paraganglioma (PGL), from 90% to less than 5%. For GATA3 to be a useful diagnostic marker for PCCs/PGLs, the reasons for such discrepancy must be elucidated. Thus, we compared different immunohistochemistry protocols. Three protocols for GATA3 immunohistochemistry, including the use of an automated slide stainer or manual staining with an autoclave and EDTA buffer vs citric acid buffer, were compared. Whole sections of paraffin-embedded tumors, including 30 PCCs, 37 PGLs including 15 head and neck PGLs, 5 retroperitoneal PGLs, 17 urinary bladder PGLs, and 14 neuroblastoma group tumors, were examined and compared with mammary and urothelial carcinoma sections as positive controls. Using the automated slide stainer (Benchmark ULTRA; Ventana Medical Systems) with both buffers, mammary and urothelial carcinomas demonstrated strong GATA3 positivity; however, PCCs/PGLs showed negative or weak heterogeneous staining. Manual staining with an autoclave for antigen retrieval resulted in increased GATA3 immunoreactivity in all head and neck PGLs, all retroperitoneal PGLs, 88% of urinary PGLs, 17% of PCCs, and all neuroblastomas, except for ganglion cells. The normal adrenal medulla stained weakly and heterogeneously. In conclusions, immunohistochemistry for GATA3 in PCCs/PGLs requires stronger antigen retrieval than that in mammary and urinary carcinomas. This finding is especially important to consider if GATA3 is applied for the differential diagnosis of PGLs in unusual sites as supplemental data to the expression of catecholamine-synthesizing enzymes.

Indexed as

Adrenal Gland NeoplasmsBiomarkers, TumorDiagnosis, DifferentialGATA3 Transcription FactorHumansImmunohistochemistryParagangliomaPheochromocytomaBiomarkers, TumorGATA3 protein, humanGATA3 Transcription FactorAntigen retrievalGATA3ImmunohistochemistryParagangliomaPheochromocytoma

Identifiers

PMID32303954
OpenAlexW3016270696

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.